曼恩凯德生物医疗(MNKD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MNKD 曼恩凯德生物医疗

休市中 10-16 16:00:00 EDT

3.04

-0.15

-4.70%

盘后3.04

+0.000.00%

19:53 EDT

最高3.24	最低3.02	成交量260.64万
今开3.20	昨收3.19	日振幅6.90%
总市值9.77亿	流通市值9.42亿	总股本3.22亿
成交额797.12万	换手率0.84%	流通股本3.10亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MNKD","market":"US","secType":"STK","nameCN":"曼恩凯德生物医疗","latestPrice":3.04,"timestamp":1792180800000,"preClose":3.19,"halted":0,"volume":2606364,"hourTrading":{"tag":"盘后","latestPrice":3.04,"preClose":3.04,"latestTime":"19:53 EDT","volume":27447,"amount":83455.233,"timestamp":1792194826234,"change":0,"changeRate":0,"amplitude":0.006579},"delay":0,"changeRate":-0.047021943573667686,"floatShares":309967022,"shares":321540637,"eps":-0.14,"marketStatus":"休市中","change":-0.15,"latestTime":"10-16 16:00:00 EDT","open":3.2,"high":3.24,"low":3.02,"amount":7971240.0623184005,"amplitude":0.068966,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.14,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1792396800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1090987200000,"exchange":"NASDAQ","adjPreClose":3.19,"preHourTrading":{"tag":"盘前","latestPrice":3.19,"preClose":3.19,"latestTime":"07:00 EDT","volume":5,"amount":15.95,"timestamp":1792148400088,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.04,"preClose":3.04,"latestTime":"19:53 EDT","volume":27447,"amount":83455.233,"timestamp":1792194826234,"change":0,"changeRate":0,"amplitude":0.006579},"volumeRatio":0.529807,"impliedVol":1.9724,"impliedVolPercentile":0.988},"requestUrl":"/m/hq/s/MNKD","defaultTab":"news","newsList":[{"id":"1164873650","title":"曼恩凯德生物医疗——将为体重管理研究提供至1B期的开发与生产支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1164873650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164873650?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:32","pubTimestamp":1788949976,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗宣布，将为一项目前处于临床1B阶段的体重管理研究提供开发及制造支持。此举不仅彰显了MannKind在生物制药领域的专业实力，也预示着其进一步扩展在代谢性疾病治疗方向的战略布局。作为一家专注于创新药物递送技术的企业，MannKind此前已在糖尿病管理领域积累了丰富经验。截至目前，关于该研究的更多细节尚未完全披露，但市场对这一消息反应积极，投资者对MannKind跨界布局的潜力充满期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4584","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168149315","title":"曼恩凯德生物医疗将获得Rose Pharma股权及未来净销售额潜在特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1168149315","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168149315?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:31","pubTimestamp":1788949896,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗公司——即将获得Rose Pharma的股权权益，并有望从未来净销售额中获取潜在的特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4584","MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195249565","title":"曼恩凯德生物医疗与Rose Pharma签署许可合作协议，共同开发吸入式速效短效GLP-1药物用于体重管理","url":"https://stock-news.laohu8.com/highlight/detail?id=1195249565","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195249565?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:31","pubTimestamp":1788949892,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗（MannKind）与Rose Pharma Inc宣布达成一项许可与合作协议，聚焦于开发一种吸入型、快速起效且作用时间较短的GLP-1药物，旨在用于体重管理领域。\n根据协议内容，双方将整合各自优势资源，共同推进这一创新疗法的研发进程。该候选药物采用吸入给药方式，区别于传统注射剂型，有望为患者提供更为便捷的治疗选择。其快速起效与短时作用的特点，或能为体重管理方案带来新的思路。\n合作双方表示，此次携手旨在加速该药物的临床开发与后续商业化进程，以应对全球范围内日益增长的肥胖及相关代谢疾病治疗需求。协议的更多细节，包括财务条款与具体分工，暂未对外完全披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4139","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125508200","title":"曼恩凯德生物医疗：售股股东拟最多抛售逾1285万股，含逾241万份认股权证股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1125508200","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125508200?lang=zh_cn&edition=full","pubTime":"2026-08-22 04:08","pubTimestamp":1787342920,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗日前提交美国证券交易委员会文件，披露一项重大股权变动计划——公司售股股东或将释放高达12,853,470股股票，值得注意的是，其中约2,412,632股源于认股权证行权所得股份。尤其值得关注的是，认股权证股份在其中所占的比重，为整体交易增添了复杂性与策略性考量。整体来看，此次SEC文件披露的信息，既反映了股东层面对公司股票流动性的管理策略，也为市场提供了关于未来股价走势的重要参考信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNKD","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193161002","title":"财报前瞻｜曼恩凯德生物医疗本季度营收预计增42.91%，机构观点偏多看改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1193161002","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193161002?lang=zh_cn&edition=full","pubTime":"2026-07-30 00:46","pubTimestamp":1785343613,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗将于2026年08月05日发布财报，市场以营收回升与利润修复为主线，关注主要合作收入与商业化产品动能变动。多家机构认为，公司在商业产品销售与版税两条线的组合提供了较好的业绩韧性，若本季度收入按一致预期增长42.91%，毛利结构有望受益于高毛利业务权重提升，从而推动EBIT与每股收益环比改善。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜曼恩凯德生物医疗本季度营收预计增42.91%，机构观点偏多看改善","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119233475","title":"曼恩凯德生物医疗公布Inflo-1 1B期积极结果：尼达尼布DPI展现安全性及耐受性，验证其特发性肺纤维化干粉吸入技术","url":"https://stock-news.laohu8.com/highlight/detail?id=1119233475","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119233475?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:32","pubTimestamp":1785321136,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗（MannKind）近日公布了Inflo-1 1B期临床试验的积极结果。该研究主要评估了尼达尼布干粉吸入剂（Nintedanib DPI）在特发性肺纤维化（IPF）患者中的安全性与耐受性。数据表明，该药物不仅展现出良好的安全特征，其耐受性也令人满意。更重要的是，此次试验结果成功验证了曼恩凯德所开发的干粉吸入（DPI）技术平台在IPF治疗领域的临床可行性。这一进展，无疑为后续的研发工作奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNKD","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120569071","title":"FDA批准曼恩凯德单次自动注射器治疗液体积聚 盘前股价飙升5.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120569071","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120569071?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:44","pubTimestamp":1784889848,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗公司（MannKind Corp）的股价在盘前交易中上涨了5.4%。这一涨幅，源于美国食品药品监督管理局（FDA）批准了该公司的一款单次使用自动注射器。该设备专门用于治疗体内液体积聚的问题。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNKD","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143305001","title":"曼恩凯德生物医疗宣布FDA批准Furoscix Readyflow™：首款用于治疗心力衰竭或慢性肾病成人水肿的静脉等效利尿剂自动注射器","url":"https://stock-news.laohu8.com/highlight/detail?id=1143305001","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143305001?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:32","pubTimestamp":1784889147,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗（MannKind）今日宣布，美国食品药品监督管理局（FDA）已正式批准其产品Furoscix Readyflow™上市。这款产品堪称业界首创，是目前唯一一款能够提供静脉等效利尿剂治疗的自动注射器，专注于解决成年心力衰竭或慢性肾病患者的顽固性水肿问题。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4139","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199926780","title":"曼恩凯德生物医疗进入数据密集开发阶段：完成Inhlo-1研究1B期随机化并启动Nintedanib DPI针对IPF患者的Inhlo-2试验2期首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1199926780","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199926780?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:11","pubTimestamp":1780481465,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗正步入一个数据密集的开发阶段。公司已成功完成其Inhlo-1研究1B期的患者随机化工作，并启动了针对特发性肺纤维化患者的Nintedanib干粉吸入剂Inhlo-2试验2期研究，首位患者已完成入组。与此同时，Inhlo-2试验2期的启动将更深入地探索Nintedanib DPI在IPF患者中的疗效与作用机制。随着这些临床研究的推进，曼恩凯德有望在未来获得大量宝贵的临床数据，为药物的进一步开发提供坚实依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4139","MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143603220","title":"曼恩凯德生物医疗宣布FDA批准Afrezza®，首个且唯一用于6岁及以上糖尿病儿童及青少年的吸入式餐时胰岛素","url":"https://stock-news.laohu8.com/highlight/detail?id=1143603220","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143603220?lang=zh_cn&edition=full","pubTime":"2026-05-30 00:30","pubTimestamp":1780072234,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗宣布，其产品Afrezza®已获得美国食品药品监督管理局的批准。该药物成为首个且唯一获批用于6岁及以上糖尿病儿童及青少年群体的吸入式餐时胰岛素。这一里程碑式的批准为这一特定年龄段的患者提供了一种全新的胰岛素给药方式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190416573","title":"曼恩凯德生物医疗获FDA解除对Afrezza的上市后要求","url":"https://stock-news.laohu8.com/highlight/detail?id=1190416573","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190416573?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:39","pubTimestamp":1779971957,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件，美国食品药品监督管理局（FDA）已于2026年5月27日解除了对曼恩凯德生物医疗（MannKind）旗下产品Afrezza的上市后要求。此举标志着该公司在满足监管机构对该吸入式胰岛素产品的特定条件方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4584","MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516548098","title":"曼恩凯德生物医疗2024财年实现净利润27.59百万美元，同比增加331.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516548098","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516548098?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931288,"startTime":"0","endTime":"0","summary":"3月3日，曼恩凯德生物医疗公布财报，公告显示公司2024财年净利润为27.59百万美元，同比增加331.07%；其中营业收入为2.86亿美元，同比增加43.72%，每股基本收益为0.10美元。从资产负债表来看，曼恩凯德生物医疗总负债4.73亿美元，其中短期债务13.12百万美元，资产负债比为0.84，流动比率为0.04。机构评级：截至2025年3月3日，当前有7家机构对曼恩凯德生物医疗目标价做出预测，其中目标均价为10.00美元，其中最低目标价为9.00美元，最高目标价为12.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000215abe4acf9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000215abe4acf9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385666","title":"曼恩凯德生物医疗盘中异动 早盘股价大跌5.21%报5.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514385666?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:31","pubTimestamp":1740666711,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时31分，曼恩凯德生物医疗股票出现异动，股价急速下挫5.21%。截至发稿，该股报5.19美元/股，成交量16.1874万股，换手率0.05%，振幅7.31%。曼恩凯德生物医疗股票所在的生物技术行业中，整体涨幅为0.06%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722315198951016&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722315198951016&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514585227","title":"曼恩凯德生物医疗盘中异动 股价大跌5.13%报5.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514585227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514585227?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:45","pubTimestamp":1740584740,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时45分，曼恩凯德生物医疗股票出现波动，股价快速下挫5.13%。截至发稿，该股报5.36美元/股，成交量90.4853万股，换手率0.33%，振幅4.51%。机构评级方面，在所有7家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.01%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226234540abddfef8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226234540abddfef8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508144336","title":"曼恩凯德生物医疗盘中异动 早盘急速跳水5.01%报5.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144336","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508144336?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:49","pubTimestamp":1738594187,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时49分，曼恩凯德生物医疗股票出现波动，股价急速跳水5.01%。截至发稿，该股报5.50美元/股，成交量45.284万股，换手率0.16%，振幅2.25%。最近的财报数据显示，该股实现营业收入70.08百万美元，净利润11.55百万美元，每股收益0.04美元，毛利52.06百万美元，市盈率69.00倍。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.34%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020322494798797234&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020322494798797234&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4584","MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2495478508","title":"曼恩凯德生物医疗盘中异动 股价大跌5.06%报6.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2495478508","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2495478508?lang=zh_cn&edition=full","pubTime":"2024-12-31 04:38","pubTimestamp":1735591125,"startTime":"0","endTime":"0","summary":"北京时间2024年12月31日04时38分，曼恩凯德生物医疗股票出现异动，股价急速下跌5.06%。截至发稿，该股报6.48美元/股，成交量151.569万股，换手率0.55%，振幅4.11%。机构评级方面，在所有6家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为1.29%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231043845a20f77da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231043845a20f77da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD","BK4139","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492444009","title":"曼恩凯德生物医疗盘中异动 早盘股价大涨5.16%报6.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492444009","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2492444009?lang=zh_cn&edition=full","pubTime":"2024-12-20 22:37","pubTimestamp":1734705463,"startTime":"0","endTime":"0","summary":"北京时间2024年12月20日22时37分，曼恩凯德生物医疗股票出现波动，股价快速上涨5.16%。截至发稿，该股报6.63美元/股，成交量51.8372万股，换手率0.19%，振幅4.60%。机构评级方面，在所有6家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.25%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220223743ab8767a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220223743ab8767a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4584","MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492184919","title":"曼恩凯德生物医疗盘中异动 股价大涨5.06%报6.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492184919","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2492184919?lang=zh_cn&edition=full","pubTime":"2024-12-18 22:53","pubTimestamp":1734533614,"startTime":"0","endTime":"0","summary":"北京时间2024年12月18日22时53分，曼恩凯德生物医疗股票出现异动，股价快速上涨5.06%。截至发稿，该股报6.23美元/股，成交量52.322万股，换手率0.19%，振幅2.85%。机构评级方面，在所有5家参与评级的机构中，80%的券商给予买入建议，20%的券商给予持有建议，无券商给予卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.48%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121822533595ea554e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121822533595ea554e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492965437","title":"曼恩凯德生物医疗盘中异动 股价大跌5.10%报5.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492965437","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2492965437?lang=zh_cn&edition=full","pubTime":"2024-12-17 22:43","pubTimestamp":1734446618,"startTime":"0","endTime":"0","summary":"北京时间2024年12月17日22时43分，曼恩凯德生物医疗股票出现异动，股价急速下跌5.10%。截至发稿，该股报5.95美元/股，成交量40.2456万股，换手率0.15%，振幅3.67%。最近的财报数据显示，该股实现营业收入70.08百万美元，净利润11.55百万美元，每股收益0.04美元，毛利52.06百万美元，市盈率74.88倍。曼恩凯德生物医疗股票所在的生物技术行业中，整体涨幅为0.56%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217224338984c908b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217224338984c908b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486015020","title":"曼恩凯德生物医疗盘中异动 快速下跌5.01%报6.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486015020","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2486015020?lang=zh_cn&edition=full","pubTime":"2024-11-26 22:43","pubTimestamp":1732632215,"startTime":"0","endTime":"0","summary":"北京时间2024年11月26日22时43分，曼恩凯德生物医疗股票出现异动，股价大幅下挫5.01%。截至发稿，该股报6.38美元/股，成交量64.4772万股，换手率0.23%，振幅3.63%。机构评级方面，在所有5家参与评级的机构中，80%的券商给予买入建议，20%的券商给予持有建议，无券商给予卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.50%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126224336abe0c251&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126224336abe0c251&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD","BK4584","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mannkindcorp.com","stockEarnings":[{"period":"1week","weight":-0.0673},{"period":"1month","weight":-0.1039},{"period":"3month","weight":-0.2084},{"period":"6month","weight":0.1232},{"period":"1year","weight":-0.3901},{"period":"ytd","weight":-0.4374}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.019},{"period":"3month","weight":0.0383},{"period":"6month","weight":0.0868},{"period":"1year","weight":0.1603},{"period":"ytd","weight":0.1318}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Mannkind Corporation于1991年2月14日在美国特拉华州注册成立。Mannkind Corporation是一家生物制药公司，侧重于诸如糖尿病和癌症之类疗法和药品的开发、研制和推广。该公司的主导候选产品——AFREZZA吸入粉末，是一种超速效胰岛素，处于后期临床研究阶段，用于成人1型或2型糖尿病高血糖的控制治疗。AFREZZA是由该公司的专有技术圈颗粒加载到胰岛素分子里。这些加载的粒子雾化吸入后，会深入到使用AFREZZA吸入器的肺部。糖尿病是一个重大的健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.681818,"avgChangeRate":0.037571},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.027316},{"month":3,"riseRate":0.409091,"avgChangeRate":-0.021457},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.018416},{"month":5,"riseRate":0.545455,"avgChangeRate":0.116663},{"month":6,"riseRate":0.545455,"avgChangeRate":0.058591},{"month":7,"riseRate":0.318182,"avgChangeRate":-0.058068},{"month":8,"riseRate":0.478261,"avgChangeRate":0.016653},{"month":9,"riseRate":0.652174,"avgChangeRate":0.074284},{"month":10,"riseRate":0.478261,"avgChangeRate":-0.041513},{"month":11,"riseRate":0.409091,"avgChangeRate":0.019784},{"month":12,"riseRate":0.545455,"avgChangeRate":-0.013619}],"exchange":"NASDAQ","name":"曼恩凯德生物医疗","nameEN":"MannKind"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"曼恩凯德生物医疗(MNKD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供曼恩凯德生物医疗(MNKD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"曼恩凯德生物医疗,MNKD,曼恩凯德生物医疗股票,曼恩凯德生物医疗股票老虎,曼恩凯德生物医疗股票老虎国际,曼恩凯德生物医疗行情,曼恩凯德生物医疗股票行情,曼恩凯德生物医疗股价,曼恩凯德生物医疗股市,曼恩凯德生物医疗股票价格,曼恩凯德生物医疗股票交易,曼恩凯德生物医疗股票购买,曼恩凯德生物医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"曼恩凯德生物医疗(MNKD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供曼恩凯德生物医疗(MNKD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}